UNSPSC 51411702: Brovincamine

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AYN5T18K5R. European Medicines Agency schedules Brovincamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05935MIG. Brovincamine generally arises in the molecular formula C21H25BRN2O3.

UNSPSC 51411702 Brovincamine is a Commodity code that captures individual pharmaceutical products for emergency medical and clinical use by state and local health systems, fire rescue services, and pharmacy benefit programs. State and local buyers under this code are procuring specific medications in bulk quantities for emergency life support protocols, regional pharmacy networks, and state-administered health plans. The code's scope reflects actual purchase activity: sealed-bid acquisitions of individual medication line items with strict expiration-date and shelf-life requirements, multi-year cooperative purchasing agreements for generic pharmaceuticals distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer prescription fulfillment programs. Issuing bodies include city purchasing departments managing emergency medical supplies (Tampa Fire Rescue), state health and human services commissions overseeing pharmacy benefit administration (Texas HHS), and multistate cooperative purchasing alliances administering pharmaceutical contracts across member jurisdictions (Minnesota MMCAP and participating states including Oregon).

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing spanning multiple states and localities. The City of Tampa's Purchasing Department solicited sealed bids (Bid No. 26-P-00188, due April 8, 2026) for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with estimated contract value of $40,000, a one-year initial term, and optional two-year renewals, including a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013, closed April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, requiring cGMP and DSCSA compliance and a 3 percent administrative fee structure.